Kurma Growth Opportunities Fund co-leads an EUR 84 million financing round for NUCLIDIUM to advance its innovative copper-based radiopharmaceutical platform for cancer treatment and diagnostics.
Target Information
NUCLIDIUM AG is a clinical-stage radiopharmaceutical company focused on developing a proprietary theranostic platform utilizing copper isotopes. The company is at the forefront of innovation in the realm of oncology, specifically aiming to improve the diagnosis and treatment of various cancers through its unique approach to radiotheranostics. By combining diagnostic and therapeutic functionalities, NUCLIDIUM's platform is designed to enhance patient outcomes and streamline clinical workflows.
The recent completion of a EUR 84 million Series B financing will enable NUCLIDIUM to push its Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline further along the clinical path, aiming to tackle multiple oncology indications. Noteworthy clinical data have already indicated superior performance when compared to existing tracers, positioning the company for significant advancements in medical imaging and treatment strategies.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The field of radiopharmaceuticals, particularly in the realm of oncological applications, is experiencing dynamic growth globally, attributed to increasing incidence rates of cancer and the demand for mo
Similar Deals
Kurma Growth Opportunities Fund
invested in
NUCLIDIUM
in 2025
in a Series B deal
Disclosed details
Transaction Size: $84M